Table 3 Effects of the two treatments on oxidative stress parameters

N

75

72

76

71

-

Sex (male/female)

37/38

36/36

36/40

35/36

ns

BMI (Kg/m²)

28.5 ± 1.3

28.4 ± 1.2

28.2 ± 1.1

28.1 ± 1.0

ns

Fasting plasma glucose (mg/dl)

129.6 ± 9.7

125.8 ± 9.1

130.1 ± 10.2

127.6 ± 9.9

ns

HbA_1c (%)

7.0 ± 0.5

6.9 ± 0.4

6.9 ± 0.4

7.0 ± 0.5

ns

Hs-CRP (mg/l)

1.7 ± 0.9

1.2 ± 0.4*

1.6 ±0.8

1.5±0.6

0.047

TNF-α (ng/ml)

2.9 ± 1.7

2.2 ± 1.3*

2.8 ± 1.6

2.6 ± 1.4

0.042

MMP-2 (ng/ml)

1216.5 ± 124.1

965.1 ± 102.6*

1218.8 ± 126.8

978.3 ± 106.2*

ns

MMP-9 (ng/ml)

465.1 ± 50.1

382.5 ± 46.3*

462.2 ± 49.4

394.1 ± 48.5*

ns

sVCAM-1 (ng/ml)

637.8 ± 172.5

536.1 ± 112.7*

638.4 ± 173.1

592.7 ± 141.6

0.041

sICAM-1 (ng/ml)

201.5 ± 12.8

174.2 ± 8.1*

204.2 ± 13.3

198.6 ± 11.2

0.046

Isoprostanes (pg/ml)

114.3 ± 39.2

92.5 ± 28.5*

110.2 ± 36.8

103.4 ± 33.2

0.047

PON-1 (U/l)

160.5 ± 85.2

182.5 ± 99.2

157.1 ± 83.4

177.2 ± 95.7

ns